-
Loading metrics
An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)
- Tarik Asselah,
- Christophe Moreno,
- Christoph Sarrazin,
- Michael Gschwantler,
- Graham R. Foster,
- Antonio Craxí,
- Peter Buggisch,
- Robert Ryan,
- Oliver Lenz,
- Jane Scott
x
- Published: July 18, 2016
- https://doi.org/10.1371/journal.pone.0158526